%0 Journal Article
%T Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome
%A Hajime Okita
%A Masahiro Fukuzawa
%A Masayuki Haruta
%A Ryuichi P. Sugino
%A Takaharu Oue
%A Takehiko Kamijo
%A Tetsuya Takimoto
%A Tsugumichi Koshinaga
%A Yasuhiko Kaneko
%A Yasuhiro Yamada
%A Yasuhito Arai
%A Yukichi Tanaka
%J Archive of "Neoplasia (New York, N.Y.)".
%D 2019
%R 10.1016/j.neo.2018.10.007
%X To identify prognostic factors, array CGH (aCGH) patterns and mutations in WT1 and 9 other genes were analyzed in 128 unilateral Wilms tumors (WTs). Twenty patients had no aCGH aberrations, and 31 had WT1 alterations [silent and WT1 types: relapse-free survival (RFS), 95% and 83%, respectively]. Seventy-seven patients had aCGH changes without WT1 alterations (nonsilent/non-WT1 type) and were subtyped into those with or without +12, 11q£¿, 16q£¿, or HACE1 loss. RFS was better for those with than those without +12 (P£¿=£¿.010) and worse for those with than those without 11q£¿, 16q£¿, or HACE1 loss (P£¿=£¿.001, .025, or 1.2E-04, respectively). Silent and WT1 type and 8 subtype tumors were integrated and classified into 3 risk groups: low risk for the silent type and +12 subgroup; high risk for the no +12 plus 11q£¿, 16q£¿, or HACE1 loss subgroup; intermediate risk for the WT1 type and no +12 plus no 11q£¿, 16q£¿, or HACE1 loss subgroup. Among the 27 WTs examined, the expression of 146 genes on chromosome 12 was stronger in +12 tumors than in no +12 tumors, while that of 10 genes on 16q was weaker in 16q£¿ tumors than in no 16q£¿ tumors. Overexpression in 75 out of 146 upregulated genes and underexpression in 7 out of 10 downregulated genes correlated with better and worse overall survival, respectively, based on the public database. +12 was identified as a potential new marker predicting a favorable outcome, and chromosome abnormalities may be related to altered gene expression associated with these abnormalities
%K WT
%K Wilms tumor
%K ROI
%K retention of imprinting
%K LOI
%K loss of imprinting
%K UPD
%K uniparental disomy
%K LOH
%K loss of heterozygosity
%K TSG
%K tumor suppressor gene
%K RFS
%K relapse-free survival
%K OS
%K overall survival
%K aCGH
%K array comparative genomic hybridization
%K miRNAPG
%K microRNA processing gene
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288985/